Review finds GLP-1 agonists ease neuroinflammation only in preclinical work

The wire

1. 01A review in Expert Review of Clinical Immunology summarizes preclinical evidence that GLP-1 receptor agonists modulate neutrophils, monocytes, T cells, microglia and astrocytes to reduce neuroinflammation in CNS disease models.
2. 02Clinicians fielding questions about repurposing incretins for neurological conditions can point to a structured summary of the mechanistic case and its limits.
3. 03The authors state clinical efficacy has not been established and call for studies linking neuroimmune biomarkers to outcomes and separating direct CNS effects from peripheral metabolic ones.

From the source

The therapeutic potential of GLP-1 receptor agonists in central nervous system diseases: immune cell modulation and neuroinflammation

Expert review of clinical immunology · 2026 Oct 8 · Wang Z, Xue S, Zhou X et al.